Editorial
doi: 10.1212/WNL.0000000000003345.
Epub 2016 Oct 19.
Rituximab for treating multiple sclerosis: Off-label but on target
Affiliations
- PMID: 27760871
- DOI: 10.1212/WNL.0000000000003345
Item in Clipboard
Editorial
Rituximab for treating multiple sclerosis: Off-label but on target
Neurology.
.
No abstract available
Similar articles
-
Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.Mult Scler Relat Disord. 2020 May;40:101980. doi: 10.1016/j.msard.2020.101980. Epub 2020 Feb 4. Mult Scler Relat Disord. 2020. PMID: 32066031
-
Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?Acta Neurol Scand. 2018 Oct;138(4):327-331. doi: 10.1111/ane.12963. Epub 2018 May 24. Acta Neurol Scand. 2018. PMID: 29797711
-
HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis.Neurol Sci. 2022 Mar;43(3):2095-2097. doi: 10.1007/s10072-021-05803-0. Epub 2022 Jan 9. Neurol Sci. 2022. PMID: 35000014 No abstract available.
-
Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.Expert Opin Ther Pat. 2011 Jan;21(1):111-4. doi: 10.1517/13543776.2011.530253. Epub 2010 Dec 15. Expert Opin Ther Pat. 2011. PMID: 21155688
-
Monoclonal antibodies in treatment of multiple sclerosis.Clin Exp Immunol. 2014 Mar;175(3):373-84. doi: 10.1111/cei.12197. Clin Exp Immunol. 2014. PMID: 24001305 Free PMC article. Review.
Cited by
-
Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Cohort Study.J Clin Med. 2022 Jun 22;11(13):3584. doi: 10.3390/jcm11133584. J Clin Med. 2022. PMID: 35806869 Free PMC article.
-
Health economics of disease-modifying therapy for multiple sclerosis in the United States.Ther Adv Neurol Disord. 2021 Feb 17;14:1756286420987031. doi: 10.1177/1756286420987031. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33643441 Free PMC article. Review.
-
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies.Degener Neurol Neuromuscul Dis. 2017 Feb 1;7:31-45. doi: 10.2147/DNND.S100096. eCollection 2017. Degener Neurol Neuromuscul Dis. 2017. PMID: 30050376 Free PMC article. Review.
-
The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.Eur J Clin Pharmacol. 2018 May;74(5):663-670. doi: 10.1007/s00228-018-2429-1. Epub 2018 Feb 10. Eur J Clin Pharmacol. 2018. PMID: 29429031 Free PMC article.
-
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.Adv Ther. 2017 May;34(5):1128-1144. doi: 10.1007/s12325-017-0522-y. Epub 2017 Apr 10. Adv Ther. 2017. PMID: 28397080 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
